LYTAP-001

LYTAP-001 is a first-in-class, small (5 amino acid) cyclic peptide degrader developed by Filamon for the treatment of cancer. It functions as a lysosomal targeting peptide that binds to the highly conserved EGF-binding site on the extracellular arm of the Epidermal Growth Factor Receptor (EGFR). Unlike traditional inhibitors, LYTAP-001 triggers the sequestration of EGFR via non-clathrin endocytosis, directing the receptor-ligand complex to the lysosome for degradation. This mechanism results in an approximately 98% reduction in EGFR recycling to the cell surface and remains effective against common EGFR mutations. Currently in preclinical, IND-enabling studies, LYTAP-001 is being developed as an oral therapeutic with clinical trials anticipated to begin in 2026.

Other names

Lysosomal targeting peptide